Autolomous
Autolomous is a London-based SaaS company that provides the autoloMATE platform — a GxP-compliant digital manufacturing management system with electronic batch records, scheduling, and quality release modules purpose-built for cell and gene therapy developers, CDMOs, and NHS trusts.
- Company typePrivate
- Founded2019
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Autolomous does
Autolomous is a London-based, venture-backed software company founded in 2019 that builds the autoloMATE® platform — a cloud-native, GxP-compliant manufacturing management system purpose-built for cell and gene therapy (CGT) production. Its customers include cell and gene therapy developers (Immatics, Achilles Therapeutics, Glycostem, Nexcella, Immix BioPharma), CDMOs (Center for Breakthrough Medicines, BioCentriq, SK pharmteco, Charles River), NHS trusts (Royal Free London, NHS University of Birmingham), academic and government-backed institutions (CGT Catapult, UCL, Stanford, CIRM, City of Hope), and blood centers (Vitalant). Autolomous describes its solution as the only platform covering the full CGT manufacturing workflow — electronic batch manufacturing records (eBMR), scheduling (CLOCK), and digital batch verification (Assist) — within a single integrated suite.
The platform is built on Amazon QLDB-hosted Distributed Ledger Technology for immutable audit trails, with AES-256 encryption, TLS 1.3 in transit, two-factor authentication, and no-code configuration. It integrates with Process Analytical Technologies, LIMS (LabVantage), QMS (Ideagens Q-Pulse), and the Vineti Personalized Therapy Management platform. In May 2024, Autolomous launched autoloMATE Launchpad, the CGT industry's first free, self-service eBR Builder, creating a product-led-growth funnel for migrating teams to cGMP-compliant paid tiers. Documented outcomes include a 65% reduction in batch documentation review time, 40% reduction in manual data entry, near-zero data error rates, and elimination of paper records (894 sheets reduced to zero per batch) at the CGT Catapult Braintree Manufacturing Innovation Centre.
Autolomous monetizes through SaaS subscriptions and enterprise license agreements for cGMP-compliant tiers, supplemented by grant-funded co-development with UKRI and Innovate UK. Its go-to-market combines direct enterprise sales to pharma, CDMOs, and NHS institutions with a free self-service Launchpad tier for land-and-expand. As of May 2026, the company announced expansion of its digital orchestration solutions from CGT to wider biopharma sectors, indicating a TAM expansion strategy.
Autolomous firmographics
Firmographics- Name
- Autolomous
- Legal name
- Autolomous Limited
- Website
- https://autolomous.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Autolomous is a London-based SaaS company that provides the autoloMATE platform — a GxP-compliant digital manufacturing management system with electronic batch records, scheduling, and quality release modules purpose-built for cell and gene therapy developers, CDMOs, and NHS trusts.
- Ownership category
- akta.pro rank
Autolomous industry classification
Industry- Product category
- Cell and Gene Therapy Manufacturing Software
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
Keywords
Where Autolomous is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices5 records
Markets served
Autolomous business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- autoloMATE Platform SaaS: Cloud-based software platform providing critical manufacturing management systems for advanced therapies. Access to the platform is provided as a service including hosting, support services, and training materials. Launchpad free tier available; cGMP-compliant tiers are paid.
- License Agreements: Enterprise license agreements with therapy developers, CDMOs, and healthcare institutions for deployment of the AutoloMATE platform across their operations.
- Platform Services and Support: Services including hosting by third-party providers, live chat and email-based support, and training materials provided alongside platform access.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free self-service eBR Builder for digital planning |
| Subscription | Annual | cGMP-compliant platform tiers |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Autolomous product offering
Product offeringCore offering
Autolomous builds and licenses the autoloMATE® cloud platform for cell and gene therapy (CGT) and biopharma manufacturers. The platform replaces paper-based batch records and manual workflows with electronic batch manufacturing records (eBMR), digital scheduling (CLOCK), digital batch verification for quality release (Assist), and Chain of Identity/Custody tracking, sold as enterprise SaaS subscriptions and license agreements to CGT developers, CDMOs, NHS trusts, and biopharma organizations.
Product overview
Autolomous offers autoloMATE®, a unified digital ecosystem platform for life science organizations. The platform consists of three integrated modules: AutoloMATE eBMR (Phase 1) digitizes batch manufacturing records, AutoloMATE CLOCK (Phase 2) provides scheduling capabilities, and AutoloMATE Assist (Phase 3) handles quality review and release. Additionally, autoloMATE Launchpad provides a free tier for eBR planning. Together these solutions enable end-to-end digital orchestration of cell and gene therapy manufacturing from discovery through commercialization.
Differentiator
Problem solved
Functional benefit
Brands
- autoloMATE®: Digital platform for cell and gene therapy manufacturing management, comprising eBMR (electronic batch manufacturing records), CLOCK (scheduling), and Assist (digital batch verification) modules.
Products and services
- autoloMATE® Platform Cloud-native, GxP-compliant digital ecosystem for life science manufacturers integrating electronic batch records, scheduling, and quality release modules for cell and gene therapy manufacturing across clinical and commercial operations.
- AutoloMATE eBMR Electronic Batch Manufacturing Record module that digitizes batch records, replacing paper-based GMP documentation with electronic workflows for CGT manufacturing.
- AutoloMATE CLOCK Scheduling module that digitizes all aspects of manufacturing scheduling for critical production variables, enabling scale-up and acceleration of manufacturing workflows.
- AutoloMATE Assist Digital batch verification module supporting quality review and release of advanced therapies; the first digital batch verification solution fully integrated with electronic batch manufacturing records and scheduling capability.
- autoloMATE® Launchpad Free self-service no-code electronic batch record builder enabling teams to begin digital planning with pre-configured templates, team collaboration, and test batch execution, with migration path to cGMP-compliant paid tiers.
Quantifiable outcome
- 65% decrease in batch documentation review time, saving 100 days' work for a full-time QA professional per AAV batch
- +3 more outcomes
Companies that use Autolomous
Customer profileNamed customers23 records
Segments5 records
Ideal customer profiles4 records
Autolomous technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability3 records
Feature12 records
Autolomous partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core.
- Alexa CrăciunescucoreInternally appointed as CBO from VP of Product Commercialisation role to address increasing demand and support expansion across CGT and wider biopharma sectors.
- CGT Catapult (Cell and Gene Therapy Catapult)coreTwo-year £1.2M UKRI-funded project demonstrating digital Process Analytical Technologies in CGT manufacturing at CGT Catapult's Braintree Manufacturing Innovation Centre. Successfully validated 65% reduction in batch review time and 40% reduction in manual data entry.
- Adva BiotechnologycoreDigital PIONEER Program launched to enable decentralized, scalable cell therapy manufacturing. GenCART Inc. joins as first clinical participant.
- BioCentriqcoreCollaboration to digitize and accelerate process development and manufacturing activities. BioCentriq leverages autoloMATE platform to streamline operations and enhance client experience for faster patient access to cell therapies.
- Center for Breakthrough Medicines (CBM)coreLicense agreement for CBM to design, configure and integrate AutoloMATE solutions across their manufacturing operations. CBM is the world's largest single CGT manufacturing site in Philadelphia.
- Royal Free London NHS TrustcoreTwo-year digitalization program for the Trust's Centre for Cell Gene Tissue Therapeutics (CCGTT). Autolomous leading deployment of AutoloMATE alongside LabVantage LIMS and Ideagens Q-Pulse QMS integration.
- VineticoreStrategic non-exclusive collaboration integrating Autolomous' manufacturing management systems with Vineti's Personalized Therapy Management platform for end-to-end CGT supply chain management. First integration of manufacturing platform with Cell Orchestration Platform.
- Steven BinningercoreAppointed as Head of Process Science and Technology to lead next phase of integration strategy, building partnerships across CGT suppliers for manufacturing verticals.
- UKRI (UK Research and Innovation)core£1M joint grant for 'Empowering the NHS advanced therapies ordering prototype IT system' project. In collaboration with University of Birmingham and University Hospitals Birmingham NHS Foundation Trust for MW-ATTC.
- Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC)coreUKRI-funded project enhancing scheduling and manufacturing of advanced therapies within UK NHS through industry-first eBMR integration with NHS advanced therapies ordering system.
- Bio-TechnecorePartnership to implement electronic batch record system at Bio-Techne's GMP cellular manufacturing center, supporting TcBuster gene delivery system and contract manufacturing services.
- Achilles TherapeuticscoreLicense agreement for AutoloMATE platform deployment to support GMP operations and electronic batch manufacturing records for T cell therapy development targeting solid tumors.
- Glycostem TherapeuticscoreCommercial contract to digitize Glycostem's NK-cell therapy manufacturing process for clinical trials and beyond. First application of AutoloMATE to an allogeneic process.
Scale indicators9 records
Recent moves8 records
Expansion highlights7 records
Autolomous competitors and assessment
Company assessmentDirect peers
- Apprentice.io: Apprentice.io provides a manufacturing execution and workflow platform purpose-built for life sciences, including cell and gene therapy production. It is the most direct competitive analog to Autolomous' autoloMATE in CGT manufacturing digitization.
- Tulip Interfaces: Tulip offers a frontline operations / manufacturing app platform widely adopted in life sciences and pharma. It competes with autoloMATE in the no-code digital batch record and connected-manufacturing space.
- Vineti: Vineti's Personalized Therapy Management platform orchestrates cell and gene therapy supply chains and is both a strategic integration partner and a directly comparable CGT-orchestration software peer.
- LabVantage Solutions: LabVantage is a leading LIMS provider and an active Autolomous integration partner (Royal Free London deployment). It is a direct peer in laboratory and manufacturing data management for life sciences.
Broad incumbents
- MasterControl: MasterControl is an established QMS/MES vendor for life sciences and medical devices with overlapping eBMR and quality capabilities. It is a broader incumbent that Autolomous competes against for GxP buyers.
- Veeva Systems: Veeva is the dominant life sciences cloud platform spanning CRM, quality, regulatory, and clinical. It is a broad incumbent that could expand its footprint into CGT manufacturing operations where Autolomous plays.
- BIOVIA (Dassault Systèmes): BIOVIA provides scientific informatics, manufacturing, and quality solutions to biopharma. It is a broad incumbent whose portfolio overlaps with autoloMATE in manufacturing data and quality for life sciences.
- Siemens Opcenter (Siemens Digital Industries): Siemens Opcenter is a broad enterprise MES suite used across regulated industries including life sciences. It competes with Autolomous for batch manufacturing record and quality workflows at large CDMOs and pharma manufacturers.
Emerging players
- Kneat Solutions: Kneat offers a digital validation and commissioning platform heavily used in life sciences GxP environments. It is an emerging peer in adjacent GxP digitization workflows.
- Dot Compliance: Dot Compliance delivers a Salesforce-native QMS solution for life sciences, overlapping with Autolomous' quality and compliance modules in the CGT and broader biopharma market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Autolomous social profiles
Digital presenceAutolomous compliance and trust
Trust signalCompliance12 records
Autolomous financial estimates
Financial estimateRevenue estimate
Valuation estimate
Autolomous leadership team
Management profileNumber of profiles
Profiles7 records
Autolomous funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Autolomous M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Autolomous
What does Autolomous do?
Autolomous builds and licenses the autoloMATE® cloud platform for cell and gene therapy (CGT) and biopharma manufacturers. The platform replaces paper-based batch records and manual workflows with electronic batch manufacturing records (eBMR), digital scheduling (CLOCK), digital batch verification for quality release (Assist), and Chain of Identity/Custody tracking, sold as enterprise SaaS subscriptions and license agreements to CGT developers, CDMOs, NHS trusts, and biopharma organizations.
Is Autolomous a public or private company?
Autolomous is a private company. It is classified as venture growth investor backed and is currently operating.
When was Autolomous founded?
Autolomous was founded in 2019. It employs 11 to 50 people.
Where is Autolomous based?
Autolomous is headquartered in London, United Kingdom, in the Europe region.
How does Autolomous make money?
Three revenue lines are on record. autoloMATE Platform SaaS are the primary driver. The others are license Agreements and platform Services and Support.
Who are Autolomous's main competitors?
Direct peers on record are Apprentice.io, Tulip Interfaces, Vineti and LabVantage Solutions. Broad incumbents are MasterControl, Veeva Systems, BIOVIA (Dassault Systèmes) and Siemens Opcenter (Siemens Digital Industries). Emerging players are Kneat Solutions and Dot Compliance.
Does Autolomous have an API?
Yes. Autolomous API enables systems integration with the autoloMATE platform. The Launchpad Terms reference API access for the purpose of systems integration, stating users shall not be granted rights to the back-end data access layer except via an Autolomous API. The platform also integrates with Vineti's notifications API for order lifecycle management.
What industry is Autolomous in?
Autolomous's product category is Cell and Gene Therapy Manufacturing Software. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its SIC code is 7372.